|M VENTURES||Principal||The Netherlands|
On which bases does the pharma decide to get involved in the Venture Capital arena?
Cheryl Zimberlin, PhD, is part of M Ventures, the corporate Venture Capital arm of Merck KgAA. M Ventures takes an active role in company creation and investment, with the mandate to invest in innovative technologies and products with the potential to significantly impact Merck‘s core businesses. Prior to joining the team she had a successful academic career at top-tier Universities, with a good track record publishing in top-tier academic journals, including Nature. She holds a PhD in Oncology and MSc in Biotechnology. Currently she holds board positions in several M Ventures portfolio companies.